Equities analysts expect that GlycoMimetics Inc (NASDAQ:GLYC) will report earnings of ($0.26) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for GlycoMimetics’ earnings, with estimates ranging from ($0.27) to ($0.25). GlycoMimetics reported earnings per share of ($0.36) during the same quarter last year, which indicates a positive year-over-year growth rate of 27.8%. The business is scheduled to announce its next earnings results on Wednesday, March 7th.

According to Zacks, analysts expect that GlycoMimetics will report full year earnings of ($1.12) per share for the current year, with EPS estimates ranging from ($1.15) to ($1.11). For the next fiscal year, analysts forecast that the company will report earnings of ($0.86) per share, with EPS estimates ranging from ($1.73) to $0.34. Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for GlycoMimetics.

GlycoMimetics (NASDAQ:GLYC) last posted its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.24) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.04.

GLYC has been the topic of a number of recent research reports. Zacks Investment Research upgraded GlycoMimetics from a “hold” rating to a “buy” rating and set a $13.00 price objective on the stock in a research note on Monday, November 13th. Jefferies Group restated a “buy” rating and set a $16.00 price objective on shares of GlycoMimetics in a research note on Thursday, October 26th. Roth Capital started coverage on GlycoMimetics in a report on Monday, October 23rd. They issued a “buy” rating and a $25.00 target price on the stock. Stifel Nicolaus reaffirmed a “buy” rating and issued a $23.00 target price on shares of GlycoMimetics in a report on Thursday, December 14th. Finally, SunTrust Banks raised their target price on GlycoMimetics to $32.00 and gave the company a “buy” rating in a report on Tuesday, December 12th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $21.00.

In other GlycoMimetics news, SVP Helen M. Thackray sold 2,000 shares of the firm’s stock in a transaction on Friday, December 8th. The stock was sold at an average price of $15.01, for a total value of $30,020.00. Following the sale, the senior vice president now owns 148,615 shares of the company’s stock, valued at approximately $2,230,711.15. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 43.80% of the company’s stock.

Several hedge funds have recently modified their holdings of GLYC. Dynamic Technology Lab Private Ltd acquired a new stake in shares of GlycoMimetics in the 2nd quarter valued at $146,000. Fox Run Management L.L.C. acquired a new stake in shares of GlycoMimetics in the 3rd quarter valued at $173,000. Citadel Advisors LLC acquired a new stake in shares of GlycoMimetics in the 2nd quarter valued at $249,000. Russell Investments Group Ltd. boosted its holdings in shares of GlycoMimetics by 172.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 31,379 shares of the biotechnology company’s stock valued at $350,000 after purchasing an additional 19,859 shares in the last quarter. Finally, Virtu KCG Holdings LLC acquired a new stake in shares of GlycoMimetics during the 2nd quarter valued at $569,000. 86.66% of the stock is currently owned by hedge funds and other institutional investors.

GlycoMimetics (GLYC) opened at $18.79 on Wednesday. GlycoMimetics has a 52 week low of $3.82 and a 52 week high of $21.40. The company has a market capitalization of $645.21, a price-to-earnings ratio of -15.15 and a beta of 3.21.

COPYRIGHT VIOLATION NOTICE: “-$0.26 Earnings Per Share Expected for GlycoMimetics Inc (GLYC) This Quarter” was first posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/01/17/0-26-earnings-per-share-expected-for-glycomimetics-inc-glyc-this-quarter.html.

GlycoMimetics Company Profile

GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.

Get a free copy of the Zacks research report on GlycoMimetics (GLYC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for GlycoMimetics (NASDAQ:GLYC)

Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.